About Survodutide
Survodutide is studied as a dual GLP-1 receptor and glucagon receptor agonist in metabolic research. Supplied as a lyophilized powder for laboratory investigations into incretin/glucagon receptor pharmacology and energy-metabolism pathway markers in controlled experimental models. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?
Recent research on Survodutide: Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?
Read Full Study on PubMedThe Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.
Recent research on Survodutide: The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.
Read Full Study on PubMedAdditional Studies
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Recent research on Survodutide: Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Read on PubMedSurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Recent research on Survodutide: Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Read on PubMedGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Recent research on Survodutide: Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Read on PubMedNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Recent research on Survodutide: Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Read on PubMedEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Recent research on Survodutide: Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Read on PubMedPharmacological management of obesity: Current landscape and emerging therapies.
Recent research on Survodutide: Pharmacological management of obesity: Current landscape and emerging therapies.
Read on PubMedRelated Research
Purchase Survodutide from Origin Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.